Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Inclusion Criteria:

18 years or older
Stage IIIb, metastatic, or recurrent NSCLC patients who have received one prior platinum-based chemotherapy regimen
ECOG performance status score of 0 or 1

Exclusion Criteria:

Laboratory values indicating inadequate function of bone marrow, liver, or kidneys
Symptomatic or uncontrolled brain metastases
Evidence of meningeal metastasis
> 1 prior regimen (not counting adjuvant or neo-adjuvant cytotoxic chemotherapy if completed > 12 months prior to regiment)
Medical condition that would increase risk if treated with motexafin gadolinium or impair ability to complete study procedures and assessments